Menotropin (hMG) and idiopathic oligoastenoteratozoospermia (OAT): effects on seminal fluid parameters and on results in ICSI cycles.
Many studies on gonadotropin treatment in idiopathic OAT have produced inconsistent (75 IU FSH + 75 IU LH) at the dosage of 3 ampoules a week for 90 days in 18 patients with idopathic OAT and testicular volume 12-15 ml. At the end of the cycle seminal fluid parameters and testicular volume were reassessed, comparing them with a homogenous control group including 13 subjects awaiting ICSI, who were not given any kind of pharmacological treatment. Treatment produced a statistically significant improvement in spermatozoa concentration (p = 0.016) and reduction in atypical forms (p = 0.040). We assessed also the impact on oocyte fertilization and pregnancy rates after the use of assisted reproduction techniques in a more restricted group of 8 patients, who had already undergone ICSI cycles before pharmacological therapy. Treatment with menotropin (hMG) appears to improve embryo quality.
Beretta
Giovanni
G
Andrology Unit, Sexuality Fertility Italian Center Milan, Florence, Italy. staff@cifs.it
Fino
Egidio
E
Sibilio
Luigi
L
Dilena
Michelangelo
M
D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008596:Menotropins / Q000627:therapeutic use*; D009845:Oligospermia / Q000188:drug therapy*; D011247:Pregnancy / Q000706:statistics & numerical data; D012661:Semen / Q000187:drug effects; D020554:Sperm Injections, Intracytoplasmic
D008596:Menotropins